Velorum Therapeutics (YC W24) — Breakthrough medicines unlocking the biology of heme
Velorum Therapeutics is developing breakthrough medicines by unlocking the biology of heme.
Velorum Therapeutics is a Y Combinator company in the Winter 2024 batch. Its directory entry describes it as: Breakthrough medicines unlocking the biology of heme. The founders listed are Pouya Modareszadeh (Founder/CEO), Parsa Modareszadeh (Founder/COO) (Y Combinator directory entry, January 31, 2024).
Get an email when Velorum Therapeutics changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
Velorum Therapeutics | Unlocking the Biology of Heme
Creating transformational medicines by unlocking the biology of heme.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Counted only where a thread links to this company's own site, announces it by name on that forum, or names it beside its own Y Combinator batch. A thread whose title merely carries the words is not counted — a name is not an identifier. Hacker News is not us, and nothing above is our opinion of the company.
Pouya Modareszadeh
Founder/CEO
Co-Founder & CEO @ Velorum Therapeutics. Building new medicines.
Parsa Modareszadeh
Founder/COO
Co-Founder and President @ Velorum Therapeutics. Goldwater Scholar. Working to create breakthrough medicines for devastating diseases.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 65 companies held here in Healthcare › Therapeutics.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on Velorum Therapeutics?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Velorum Therapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Velorum Therapeutics covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Velorum Therapeutics: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
